Jared Whitlock

For families, a $2.1M medicine can feel like both a miracle and an out-of-reach reality. Now, biotechs in China are racing to develop lower-cost alternatives: endpoints.news/chinese-biotec…

(3/3) I’ll continue covering topics like China, rare disease research and genetic testing, as well as report on areas outside healthcare and biotech that catch my interest.

(2/3) Thank you to @ArmstrongDrew, @lydiapflanzer and all there. After a break, I’ll dive back into freelance work. If you're looking for features, profiles or investigative pieces, I’d love to connect. Before Endpoints, I wrote for outlets like Wired and Voice of San Diego.

(1/3) Some personal news: After nearly four years at @endpts, I’m returning to freelance journalism. It's been a meaningful time. I've been lucky to be a part of Endpoints as the newsroom grew, picked up numerous awards and gained readers.

Reporting here: endpoints.news/china-is-takin…

ICYMI: Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans

China competition is coming for the US's multimillion-dollar gene therapies -- a must-read from @Jared_Whitlock about what's happening there and how it will affect access around the world: endpoints.news/china-is-takin…

Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans My latest feature for @endpts, complete with data analysis. endpoints.news/china-is-takin…

Did the FDA’s individualized therapy guidance put a spike in the heart of a startup biotech? Fake news, says the HHS. Yeah, it did, says an insider. Exclusive from @RLCscienceboss and @Jared_Whitlock endpoints.news/everyone-medic…

EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway endpoints.news/everyone-medic…

Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway From @RLCscienceboss and me: endpoints.news/everyone-medic…

Hey everyone! I'm starting a monthly newsletter on @Substack of curated longform journalism recommendations. I'll be highlighting the stories that've stuck with me the most each month + two books & a podcast. 1st post here. Please subscribe and share! open.substack.com/pub/thelongfor…

After rallying, Grail's cancer test faces new uncertainty due to UK study My latest via @endpts: endpoints.news/grails-cancer-…

A Chinese biotech says its gene therapy slowed aggressive brain cancer in an early human test, but the debated approach is already drawing skepticism from some researchers. My latest. @endpts endpoints.news/neuexcell-ther…

Honored to have won a George Polk award for my coverage of the turmoil at FDA last year. The STAT team was also recognized for reporting on the Trump admin's impact on health and science. statnews.com/2026/02/18/sta…

With a valuation of about $61 billion, Hengrui is now larger than Takeda and Bayer. But there’s still one big item on its bucket list: selling its own treatments outside of China. My story in @endpts: endpoints.news/hengrui-blazes…

At #JPM26, pharma leaders said the US should focus on fixing its own biopharma system, not slowing China’s rise in drug development. endpoints.news/jpm26-drugmake…

Dispatch from #JPM2026: Drugmakers and investors want US reforms, not to slow down China endpoints.news/jpm26-drugmake…

You know the China biotech story is here to stay when Endpoints starts hiring in Hong Kong. Exciting opportunity!

Pre-JPM news flow update: The embargoes are so plentiful that our copy editor is drawing filed stories from a hat.

📢Some BIG news here at Endpoints: We're building in China. This year, we'll be hiring a senior journalist in Hong Kong who can lead on our coverage of China biotech. This is one of biotech's most important stories. Want to shape it? DM me, or apply. ats.rippling.com/endpointsnews/…